Why Diagnostics Is Hard: Three Extra Challenges And How Startups Can Still Succeed

2 min read

Diagnostics shares the same two key challenges as most of digital health. One, long sales cycles of 9-18 months into providers, often even longer for payors and pharma. Two, FDA approval that necessitates clinical trials and typically adds a couple years before the company can commercialize its product. But diagnostics has a high degree of some additional challenges. And let’s not dismiss the backlash that Theranos caused — much has been written about it, including the bestseller “Bad Blood.”  This post offers a framework for how startups can tackle the beasts of recurrence, distribution and reimbursement — and still succeed…....

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.